Bristol-Myers Squibb Company
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use

Abstract:

There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.